Rosette formation and inhibition in cervical dysplasia and carcinoma in situ.
Total and early rosettes and rosette inhibition were measured in patients with cervical dysplasia and carcinoma in situ. Both total and early rosettes were significantly depressed in patients with carcinoma in situ; early rosettes were also significantly lower than were controls in women with severe dysplasia. Rosette inhibition titers were increased in most patients with moderate dysplasia and in all patients with either severe dysplasia or carcinoma in situ. Thus, the Rosette inhivition test may be useful in detecting, in a precancerous state, patients at risk for cancer.
D000328:Adult; D000368:Aged; D002278:Carcinoma in Situ / Q000276:immunology*; D004912:Erythrocytes / Q000276:immunology; D005260:Female; D006801:Humans; D008214:Lymphocytes / Q000276:immunology; D008875:Middle Aged; D011230:Precancerous Conditions / Q000276:immunology*; D012397:Rosette Formation; D002578:Uterine Cervical Dysplasia / Q000276:immunology*; D002583:Uterine Cervical Neoplasms / Q000276:immunology*